Sangamo Therapeutics Aktie
WKN: 936386 / ISIN: US8006771062
20.09.2023 22:15:00
|
Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced that it will participate in the Jefferies Cell & Genetic Medicine Summit, to be held from September 26-27, 2023 in New York City.
Sandy Macrae, Sangamo’s President and Chief Executive Officer is scheduled to present on Wednesday, September 27th at 11:00AM ET. A live webcast of the presentation will be available here and on the Company’s Investor Events webpage. A replay of the presentation will be available on the Sangamo Therapeutics website for 90 days after the event.
About Sangamo Therapeutics
Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline. Using ground-breaking science, including our proprietary zinc finger genome engineering technology and manufacturing expertise, Sangamo aims to create new genomic medicines for patients suffering from diseases for which existing treatment options are inadequate or currently don’t exist. To learn more, visit www.sangamo.com and connect with us on LinkedIn and Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230920374990/en/

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Sangamo Therapeutics Incmehr Nachrichten
07.10.25 |
NASDAQ Composite Index-Titel Sangamo Therapeutics-Aktie: So viel hätten Anleger mit einem Investment in Sangamo Therapeutics von vor 5 Jahren verloren (finanzen.at) | |
07.10.25 |
Pluszeichen in New York: NASDAQ Composite steigt zum Handelsstart (finanzen.at) | |
02.10.25 |
NASDAQ-Handel: NASDAQ Composite legt nachmittags zu (finanzen.at) | |
30.09.25 |
Handel in New York: NASDAQ Composite nachmittags in Rot (finanzen.at) | |
30.09.25 |
Dienstagshandel in New York: NASDAQ Composite am Dienstagmittag leichter (finanzen.at) | |
30.09.25 |
NASDAQ Composite Index-Wert Sangamo Therapeutics-Aktie: So viel hätte eine Investition in Sangamo Therapeutics von vor 3 Jahren gekostet (finanzen.at) | |
29.09.25 |
Freundlicher Handel: Anleger lassen NASDAQ Composite am Nachmittag steigen (finanzen.at) | |
29.09.25 |
Aufschläge in New York: NASDAQ Composite mittags mit Kursplus (finanzen.at) |
Analysen zu Sangamo Therapeutics Incmehr Analysen
Aktien in diesem Artikel
Sangamo Therapeutics Inc | 0,58 | -2,07% |
|